Key facts
- Mezzion Pharma announced the completion of a regulatory milestone for its FUEL-2 Phase 3 study.
- An independent, blinded statistical review was conducted.
- The study will continue as planned following the review.
- Enrollment for the study is on track for completion in 2026.
Mezzion Pharma Co., Ltd. announced on June 5, 2026, the completion of a planned independent, blinded statistical review for its FUEL-2 Phase 3 study. Following this review, the company confirmed that the study will proceed as planned. Enrollment for the study is currently on track to be completed in 2026. Mezzion Pharma is listed on KOSDAQ under the ticker 140410.